儿童淋巴瘤分期与预后评估中FDG PET成像的进展:一项系统综述
该系统综述纳入31项研究,评估[18F]FDG-PET、PET/CT和PET/MRI在儿童淋巴瘤无创分期、疗效评估和预后判断中的价值。结果显示[18F]FDG-PET(单独或联合CT/MRI)在诊断、分期和随访各阶段敏感度和阴性预测值(>70%)高于传统影像,但阳性预测值仍中等(<50%);PET/CT预后价值优于单独PET或MRI;随访时PET/MRI阳性预测值优于传统影像。作者指出辐射暴露、MRI覆盖范围有限和预测值多变等问题需谨慎应用,代谢肿瘤体积和总病灶糖酵解等参数有额外预后潜力但需进一步标准化和前瞻性验证。
要点
- [18F]FDG-PET联合CT或MRI可提高儿童淋巴瘤淋巴结和结外病变的检出,改善诊断准确性和分期。
- PET/CT的预后价值优于单独PET或MRI,随访时PET/MRI的阳性预测值优于传统影像。
- PET可显示早期代谢变化,支持及时评估治疗反应,并可能减少有创骨髓活检的需求。
核心结论
- 核心结论:[18F]FDG-PET联合CT或MRI通过改善淋巴结和结外病变的检出,提高儿童淋巴瘤的诊断准确性和分期;PET显示早期代谢变化的能力支持及时评估治疗反应,并可能减少有创骨髓活检的需求;但辐射暴露、MRI覆盖范围有限和预测值多变等问题提示在儿童中需谨慎应用;代谢肿瘤体积和总病灶糖酵解等高级参数提供额外预后潜力,但需进一步标准化和前瞻性验证。
研究设计与样本
- 研究设计:系统综述,检索PubMed、Scopus和Web of Science(2011-2024年),纳入31项符合标准的研究,提取研究设计、人口学、成像方案、示踪剂剂量和定量PET参数等数据。
关键影像表现/征象
- 关键影像表现:[18F]FDG-PET(单独或联合CT/MRI)在诊断、分期和随访阶段持续显示比传统影像更高的敏感度和阴性预测值(>70%),但阳性预测值仍中等(<50%);PET/CT提供的预后价值比单独PET或MRI更可靠;随访时PET/MRI的阳性预测值优于传统影像,后者效用有限。
诊断标准与关键数值
- 诊断标准与关键数值:定量分析主要依赖标准化摄取值(SUV),并额外使用代谢肿瘤体积和总病灶糖酵解;[18F]FDG-PET(单独或联合CT/MRI)在诊断、分期和随访阶段的阴性预测值>70%,阳性预测值<50%。
临床应用与阅片要点
- 临床应用与阅片要点:作者认为[18F]FDG-PET联合CT或MRI可提高儿童淋巴瘤诊断准确性和分期,PET显示的早期代谢变化支持及时评估治疗反应并可能减少有创骨髓活检的需求;但作者指出辐射暴露、MRI覆盖范围有限和预测值多变等问题需谨慎应用;代谢肿瘤体积和总病灶糖酵解等高级参数有额外预后潜力但需进一步标准化和前瞻性验证。
局限性
- 局限性:原文指出辐射暴露、MRI覆盖范围有限和预测值多变等问题;高级参数如代谢肿瘤体积和总病灶糖酵解需进一步标准化和前瞻性验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: Lymphoma is a significant pediatric cancer, following acute leukemia and malignant brain tumors. Traditional diagnostic and staging methods, such as biopsies and the Ann Arbor system, may have limitations in accuracy and invasiveness. This systematic review aims to critically evaluate the utility of fluorine-18 fluorodeoxyglucose-positron emission tomography ([18F]FDG-PET), positron emission tomography/computed tomography (PET/CT), and positron emission tomography/magnetic resonance imaging (PET/MRI) in improving non-invasive staging, treatment response evaluation, and prognostic values in pediatric lymphoma.
METHOD: A systematic search of PubMed, Scopus, and Web of Science was conducted (2011-2024) using keywords related to pediatric lymphoma and PET. Data were extracted on study design, demographics, imaging protocols, tracer dosing, and quantitative PET parameters.
RESULTS: Thirty-one studies met the eligibility criteria. Quantitative analysis primarily relied on the standardized uptake value (SUV), with additional use of metabolic tumor volume and total lesion glycolysis. Across diagnostic, staging, and follow-up phases, [18F]FDG-PET (alone or combined with CT/MRI) consistently showed higher sensitivity and the negative predictive value (NPV) (>70%) than conventional imaging, though the positive predictive value remained moderate (<50%). PET/CT provided more reliable prognostic value than PET alone or MRI. At follow-up, PET/MRI demonstrated better positive predictive value (PPV) than conventional imaging, which showed limited utility.
CONCLUSION: [18F]FDG-PET combined with CT or MRI enhances diagnostic accuracy and staging of pediatric lymphoma by improving the detection of nodal and extranodal disease. PET's ability to reveal early metabolic changes supports timely assessment of treatment response and may reduce the need for invasive bone marrow biopsies. Nonetheless, concerns about radiation exposure, limited MRI coverage, and variable predictive value highlight the need for cautious application in children. Advanced parameters such as metabolic tumor volume and total lesion glycolysis offer additional prognostic potential, but further standardization and prospective validation are required. Overall, PET represents a promising, less invasive tool for staging and follow-up, with the potential to improve both diagnostic precision and patient outcomes.
CLINICAL TRIAL NUMBER: Not applicable.
引用
- Ghazi FM, Shafiei S, SeyedAlinaghi S, et al. Advances in FDG PET imaging for staging and prognostic assessment in pediatric lymphoma: a systematic review. Pediatr Radiol. 2025. PMID: 41348237. doi:10.1007/s00247-025-06476-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。